USPTO serial 97092446
EMPOWERPHARM
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- DUONG, ANGELA GAW
- Law office
- TMO LAW OFFICE 130
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with EMPOWERPHARM?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Burlington, Ontario, CA
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Nicole K. McLaughlin
Nicole K. McLaughlin DUANE MORRIS LLP30 SOUTH 17TH STREETPHILADELPHIA, PA 19103-4196UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations containing synthetic cannabidiol (CBD) for the treatment of various diseases, conditions and disorders; Pharmaceutical preparations containing synthetic cannabidiol (CBD) for the treatment of anxiety, stress, pain and insomnia; Pharmaceutical preparations containing synthetic cannabidiol (CBD) for the treatment of anxiety; Natural health products, namely, glucosamine, turmeric supplements, dietary supplements to aid digestion, melatonin, sleep support supplements, fish oils, probiotics in tablet, capsule, gummy vitamin and liquid form; vitamin supplements; mineral supplements; vitamin and mineral food supplements; vitamin and mineral dietary supplements; vitamin preparations; mineral preparations; multivitamins; prenatal vitamins; calcium supplements; nutritional supplements for general health and well-being, namely, magnesium in tablets, capsules, gummies, and liquids; dietary supplements for promoting weight loss; over the counter medications for treating aches, pains, headaches, arthritis pain, sprains, and for treatment of minor joint injuries and muscle soreness, nonsteroidal anti-inflammatory drugs (NSAIDs), ibuprofen, naproxen sodium, acetaminophen, cold, sore throat and cough medications, guaifenesin, liquid cough medicines with dextromethorphan, decongestant nasal sprays, pseudoephedrine, phenylephrine, allergy medications, antihistamine pills and liquids, diphenhydramine, chlorpheniramine, brompheniramine, loratadine, fexofenadine, cetirizine, stomach upset medications, namely, probiotic preparations for medical purposes to help maintain a natural balance of flora in the digestive system, antidiarrhea medicines, loperamide, bismuth, nausea treatment preparations, pharmaceutical preparations for the treatment of vomiting and motion sickness, dimenhydrinate; cannabidiol (CBD) oil for medical purposes; cannabidiol (CBD) for medical purposes; cannabidiol (CBD) for medical purposes in the form of suppositories, sublingual doses that dissolve in the mouth, creams, ointments, and doses for absorption in the mucous membranes; tablets, capsules, gummies, suppositories, skin patches, sublingual doses, extended release tablets and liquids for therapeutic purposes containing cannabidiol (CBD); herbal supplements containing cannabidiol (CBD); Liquid nutritional supplement containing cannabidiol (CBD) for treating, reducing or improving symptoms of various conditions, namely, pain, anxiety, depression, cancer, acne, skin conditions, neuroprotection, cardiovascular health, arthritis, inflammation, autoimmune conditions, epileptic seizures, nausea, appetite, inflammatory bowel disease, and insomnia; tetrahydrocannabinol (THC) for medical purposes; tetrahydrocannabinol (THC) for medical purposes in sublingual doses and doses for absorption in the mucous membranes; tablets, capsules, gummies, suppositories, skin patches, sublingual doses, extended release tablets and liquid for therapeutic purposes containing tetrahydrocannabinol (THC) and containing a combination of tetrahydrocannabinol (THC) together with cannabidiol (CBD) | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 15, 2026 | MAB2 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Sep 15, 2026 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Apr 16, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 16, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 16, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 2, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 20, 2022 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Dec 20, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Dec 20, 2022 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Nov 9, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 29, 2021 | NWAP | NEW APPLICATION ENTERED | — |